Hospital
American Healthcare Systems, LLC
American Healthcare Systems, LLC was paid $20.89M by Medicaid between Oct 2021 and Dec 2024, across 77 billing codes. Its largest line is 99285, emergency room visit (most serious) — 24% of everything it billed.
33Billing provider infoAMERICAN HEALTHCARE SYSTEMS, LLC
ASHEBORO, NC 27203
ASHEBORO, NC 27203
33aNPI1942895081assigned 03/01/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$20.89M
24GClaims162,655
24DCodes billed77
24AFirst – last monthOct 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#26 of 92
Median peer was paid$11.47M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GILL, FAISAL controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 10,267 | $1.16M | |
| 2022 | 46,672 | $5.76M | |
| 2023 | 55,832 | $7.36M | |
| 2024incomplete | 49,884 | $6.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 7,970 | 7,042 | $4.92M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 7,298 | 6,510 | $3.81M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 10,046 | 9,096 | $3.75M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 11% | 1,249 | 1,129 | $2.36M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 4.1% | 5,818 | 5,382 | $862K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.5% | 3,750 | 3,335 | $728K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 1,257 | 1,162 | $677K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 1,650 | 1,514 | $376K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 4,768 | 4,160 | $372K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 1,590 | 1,499 | $365K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 2,881 | 2,552 | $361K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,746 | 1,556 | $196K |
65 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,488 | $186K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 961 | $182K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 70 | $178K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,947 | $172K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 513 | $135K |
| J3490 | Unclassified drugs | <1% | 22,348 | $127K |
| 80053 | Comprehensive metabolic panel | <1% | 12,061 | $113K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,071 | $103K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 590 | $94K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,129 | $79K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 237 | $73K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 93 | $72K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 2,486 | $70K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 39 | $62K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 734 | $51K |
| 83880 | <1% | 1,783 | $50K | |
| 81025 | <1% | 4,024 | $39K | |
| 81001 | <1% | 9,189 | $35K | |
| 84484 | <1% | 3,550 | $34K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 518 | $33K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 16 | $28K |
| 71250 | <1% | 66 | $26K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 439 | $26K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 13 | $24K |
| 83690 | <1% | 2,441 | $19K | |
| 85730 | <1% | 2,858 | $15K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 70 | $13K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 586 | $12K |
| 85610 | <1% | 2,892 | $10K | |
| 83605 | <1% | 788 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 683 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 441 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 180 | $3K |
| 83735 | <1% | 489 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 258 | $3K |
| 84145 | <1% | 171 | $3K | |
| 85027 | <1% | 384 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 866 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,977 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 45 | $2K |
| A9270 | Non-covered item or service | <1% | 4,538 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 142 | $1K |
| 80076 | <1% | 108 | $927.55 | |
| 86140 | <1% | 152 | $899.31 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 26 | $885.24 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 26 | $885.20 |
| 81003 | <1% | 199 | $658.72 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 54 | $533.43 |
| 85007 | <1% | 126 | $489.59 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 163 | $448.99 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 82 | $444.37 |
| 82962 | <1% | 143 | $341.99 | |
| 85651 | <1% | 72 | $293.10 | |
| 82550 | <1% | 44 | $265.59 | |
| 87040 | <1% | 21 | $245.60 | |
| 87077 | <1% | 26 | $226.85 | |
| 85379 | <1% | 12 | $201.60 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 39 | $198.18 |
| 87081 | <1% | 27 | $179.57 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 18 | $156.91 |
| 81002 | <1% | 64 | $156.91 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 13 | $141.85 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 16 | $113.28 |
| 87210 | <1% | 12 | $64.71 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15 | $24.24 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGILL, FAISAL (LEGAL COUNSEL)
| Provider | Location | Paid |
|---|---|---|
| American Healthcare Systems, LLC | Asheboro, NC | $5.30M |
| American Healthcare Systems, LLC | Asheboro, NC | $1.44M |
| American Healthcare Systems, LLC | Asheboro, NC | $561K |
| American Healthcare Systems, LLC | Liberty, NC | $322K |
| American Healthcare Systems, LLC | Asheboro, NC | $251K |
| American Healthcare Systems, LLC | Asheboro, NC | $237K |
| American Healthcare Systems, LLC | Asheboro, NC | $111K |
| American Healthcare Systems, LLC | Asheboro, NC | $63K |
| American Healthcare Systems, LLC | Asheboro, NC | $59K |
| American Healthcare Systems, LLC | Asheboro, NC | $53K |
| American Healthcare Systems, LLC | Seagrove, NC | $46K |
| American Healthcare Systems, LLC | Asheboro, NC | $17K |
| American Healthcare Systems, LLC | Asheboro, NC | $956.65 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.